Výsledky vyhledávání - "Activating RAS Mutation"

Combined melanocytic and sweat gland neoplasm: cell subsets harbor an identical HRAS mutation in phacomatosis pigmentokeratotica

Autor: Michael F. Berger, Janet Y. Li, Ashfaq A. Marghoob, Melissa Pulitzer, Jennifer P. Toyohara, Umesh Bhanot

Publikováno v: Journal of Cutaneous Pathology. 41:663-671

Phacomatosis pigmentokeratotica (PPK) is characterized by the co-existence of epidermal nevi and large segmental speckled lentiginous nevi of the papulosa type. PPK, previously explained as 'twin spot' mosaicism due to the postzygotic crossing-over o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::046455594f4733fce7cf86131b28a60a
https://doi.org/10.1111/cup.12339

Zobrazit plný text záznamu

Plný text ve formátu HTML

Decreased susceptibility to NMU-induced mammary carcinogenesis in transgenic rats carrying multiple copies of a rat ras gene driven by the rat Harvey ras promoter

Autor: Todd A. Thompson, Anne E. Griep, Jill D. Haag, Mary J. Lindstrom, Michael N. Gould, Jan K. Lohse

Publikováno v: Oncogene. 21:2797-2804

Ras protein over-expression has been observed in human breast cancers although the significance of Ras over-expression in the etiology of breast cancer is unknown and its contribution to breast cancer prognosis is still debated. In this study, the ov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c45a3e3ade87e9dae0a34bf47b69b0b3
https://doi.org/10.1038/sj.onc.1205391

Zobrazit plný text záznamu

Abstract 5170: HDAC inhibitors and the mechanism of resistance in colorectal cancer: RAS and MYC - the partners in crime

Autor: Natalia Kuhn, Tilman Brummer, Bastian Gastl, Lena Boehme, Christine Sers, Martin Eilers, Kathleen Klotz-Noack, Sylvia Ispasanie

Publikováno v: Cancer Research. 77:5170-5170

Although histone deacetylase inhibitors (HDACi) are considered a promising novel therapeutic approach in the light of their potent tumour-selective effects, the use of these inhibitors for treatment of colorectal cancer (CRC) have thus far demonstrat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee9924c89f354ada0e5c4abf4fff7017
https://doi.org/10.1158/1538-7445.am2017-5170

Zobrazit plný text záznamu

Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC)

Autor: Eduard Vrdoljak, A. Scott Jung, Nebojsa Manojlovic, Xuesong Guan, Tae Won Kim, Anneli Elme, Anghel Adrian Udrea, Joon Ho Park

Publikováno v: Journal of Clinical Oncology. 35:3561-3561

3561 Background: Activating RAS mutation is a negative predictor of anti-EGFR therapy. In the final analysis of 20100007, the first phase 3 study to prospectively evaluate efficacy and safety of WT RAS ( KRAS and NRAS exons 2, 3, 4 ) mCRC, pmab + BSC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78fce56c293778c74d6fb647507bcfc6
https://doi.org/10.1200/jco.2017.35.15_suppl.3561

Zobrazit plný text záznamu

Abstract 2148: Ras-mediated evasion of detachment-induced cell death involves differential signaling pathways for metabolism and anoikis

Autor: Cassandra L. Buchheit, Amy K. Leliaert, Sienna M. Durbin, Joshua A. Mason, Calli Versagli, Zachary T. Schafer

Publikováno v: Cancer Research. 75:2148-2148

In order for successful metastasis to occur, cells must overcome anoikis, a caspase-dependent cell death process triggered by detachment from the extracellular matrix (ECM). In addition, recent studies have revealed that ECM-detached cells must also

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0bb0895abc07b95aa7bab7d23bbd6048
https://doi.org/10.1158/1538-7445.am2015-2148

Zobrazit plný text záznamu

Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis

Autor: Susan E. Moody, Lewis A. Chodosh, Robert Boxer, Christopher J. Sarkisian, Blaine A. Keister, Douglas B. Stairs

Publikováno v: Nature cell biology. 9(5)

Activating Ras mutations can induce either proliferation or senescence depending on the cellular context. To determine whether Ras activation has context-dependent effects in the mammary gland, we generated doxycycline-inducible transgenic mice that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::475540431830d871fc9bd8a07d30a9d4
https://pubmed.ncbi.nlm.nih.gov/17473855

Zobrazit plný text záznamu

Role of Murine BRCA1 Protein Interactions in DNA Repair

Autor: Lewis A. Chodosh, Robert Boxer

Amplification of the c-MYC oncogene has been found in five to twenty percent of breast tumors However, the molecular mechanisms by which c-MYC contributes to tumorigenesis is not well understood. To address this question, we have used the tetracyclin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e314b19e2b5988a4806452150806083
https://doi.org/10.21236/ada400472

Zobrazit plný text záznamu

A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations

Autor: Allen Lee Cohn, Peter Muscarella, William E. Fisher, Frank E. Harrell, Sue Speyer, Donald A. Richards, Samuel H. Whiting, Alexander S. Rosemurgy, John Ferraro

Publikováno v: Journal of Clinical Oncology. 28:TPS226-TPS226

TPS226 Background: Patients with resected pancreas cancer treated with standard of care gemcitabine (Gem) have a median recurrence-free survival of 14 months, median overall survival of 22 months, and a survival rate of 20% at 5 years. The postresect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bb8c6215800e841eb3e7b1ecc733a75
https://doi.org/10.1200/jco.2010.28.15_suppl.tps226

Zobrazit plný text záznamu

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM)

Autor: Tammy Price-Troska, P. Leif Bergsagel, Marta Chesi, Morie A. Gertz, Greg J. Ahmann, Wee Joo Chng, Philip R. Greipp, Rafael Fonseca, Robert A. Kyle, S. Vincent Rajkumar, Kim Henderson

Publikováno v: Blood. 110:241-241

Events mediating transformation from the pre-malignant MGUS to MM is largely unknown. Previous studies have highlighted RAS mutation as a progression event. However, this abnormality is present in only a small subset of patients. Global gene expressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7271c8efcc5a3fea4505277ac7084f0d
https://doi.org/10.1182/blood.v110.11.241.241

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání